Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Omvoh ® ▼ (mirikizumab)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
Does an in-line filter need to be used when administering Omvoh® (mirikizumab) intravenously?
There is no specific requirement to use an in-line filter when administering mirikizumab intravenously. There are no contraindications for using an in-line filter with mirikizumab if a health care provider chooses to do so.
Additional Information
There is no specific requirement to use an in-line filter when administering mirikizumab intravenously. There are no contraindications for using an in-line filter with mirikizumab if a health care provider chooses to do so.1
Dilution and Administration of Omvoh
The dilution and use of the Omvoh solution for infusion are described in the Omvoh Summary of Product Characteristics (SmPC), see section
- 4.2 Posology and method of administration
- 6.6 Special precautions for disposal and other handling.2
Below is an explanation of why an in-line filter was used for the infusion of Omvoh in the VIVID-1 study. A description of the pivotal study can be found in section 5.1 of the SmPC.2
Use of In-line Filter to Maintain Blinding in the VIVID-1 study for Crohn`s Disease
In the VIVID-1 clinical trial, where ustekinumab was one of the treatment groups, an in-line filter was used for the first dose of mirikizumab to maintain study blinding.1
References
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Omvoh 300 mg concentrate for solution for infusion [summary of product characteristics] Eli Lilly Nederland B.V., The Netherlands (UK)
Links to references and third-party websites are provided solely for your convenience and to facilitate easy access to the sources cited.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: 12 July 2023